We have located links that may give you full text access.
Journal Article
Review
Modulating the Er:YAG laser.
BACKGROUND AND OBJECTIVES: In the past 2 years, there has been some controversy about the optimal laser system, or combination of systems, for cutaneous resurfacing. Initially, it seemed that the Er:YAG laser would have significant advantages over the CO(2) laser. In practice, some of those who jumped early onto the Er:YAG bandwagon have been unimpressed with the degree of skin tightening that can be achieved with this system. Also, the excessive bleeding induced by the Er:YAG lasers prevented deeper vaporization. During the past 18 months, three new "modulated" Er:YAG lasers have been produced that are said to be able to achieve CO(2) laser-like effects, while maintaining the Er:YAG laser advantages. The purpose of this article is to examine these new systems and to discuss their potential benefits, if any, over the "conventional" Er:YAG lasers, and the CO(2) lasers.
STUDY DESIGN/MATERIALS AND METHODS: The author has collected data from his own experience and that of his colleagues in the department of dermatology at University of California at San Francisco. The author has used all three types of modulated Er:YAG laser on patients presenting for cosmetic laser resurfacing and the treatment of many benign conditions over an 18-month period.
RESULTS: All three modulated forms of Er:YAG lasers have been demonstrated to provide better coagulation than the conventional Er:YAG lasers. The Derma-K and the Contour Er:YAG lasers were able to induce tissue contraction/desiccation similar to the CO(2) laser. The author and his colleagues have induced only two cases of permanent hypopigmentation in over 50 cases during the past 18 months while using the Er:YAG laser, significantly less than might be expected with the CO(2) lasers.
CONCLUSIONS: If a laser surgeon is happy with the results obtained with a high-energy, short-pulse CO(2) laser, then there seems little reason to consider changing to an Er:YAG laser. The modulated Er:YAG lasers have definite advantages over the conventional Er:YAG lasers. They exhibit better control of hemostasis and can ablate tissue to a greater depth than the conventional Er:YAG lasers. The Er:YAG lasers might induce less permanent hypopigmentation than the CO(2) lasers.
STUDY DESIGN/MATERIALS AND METHODS: The author has collected data from his own experience and that of his colleagues in the department of dermatology at University of California at San Francisco. The author has used all three types of modulated Er:YAG laser on patients presenting for cosmetic laser resurfacing and the treatment of many benign conditions over an 18-month period.
RESULTS: All three modulated forms of Er:YAG lasers have been demonstrated to provide better coagulation than the conventional Er:YAG lasers. The Derma-K and the Contour Er:YAG lasers were able to induce tissue contraction/desiccation similar to the CO(2) laser. The author and his colleagues have induced only two cases of permanent hypopigmentation in over 50 cases during the past 18 months while using the Er:YAG laser, significantly less than might be expected with the CO(2) lasers.
CONCLUSIONS: If a laser surgeon is happy with the results obtained with a high-energy, short-pulse CO(2) laser, then there seems little reason to consider changing to an Er:YAG laser. The modulated Er:YAG lasers have definite advantages over the conventional Er:YAG lasers. They exhibit better control of hemostasis and can ablate tissue to a greater depth than the conventional Er:YAG lasers. The Er:YAG lasers might induce less permanent hypopigmentation than the CO(2) lasers.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app